Home > Legal Library > Advanced Search > Search Results









Join Matindale-Hubbell Connected



Search Results (272)

  
Documents on Products Liability, Pharmaceuticals, Internet & E-Commerce
 

View Page: 1  2  3  4  5  6  7  8  9  10  Next  >>
Show: results per page
Sort by:
Sponsored Results

HTMLStudy Shows Using Antibiotics Early In Life Could Affect Immunity in the Long Term
Seth A. Katz; Burg Simpson Eldredge Hersh & Jardine, P.C.;
Legal Alert/Article
September 10, 2014, previously published on August 28, 2014
New research from the University of British Columbia has revealed that taking antibiotics early in life may harm your immunity later on. Antibiotics fight bacteria in a patient, but they don't differentiate between the good and the bad kind. As such, antibiotic treatments can end up attacking good...

 

HTMLAntibiotic Clarithromycin Linked To Increased Risk of Cardiac Death
Seth A. Katz; Burg Simpson Eldredge Hersh & Jardine, P.C.;
Legal Alert/Article
September 10, 2014, previously published on August 26, 2014
Danish researchers from the Statens Serum Institut in Copenhagen found the antibiotic clarithromycin increased the risk of cardiac-related deaths.

 

HTMLDEA Moves Hydrocodone Combination Drugs to Schedule II
Seth A. Katz; Burg Simpson Eldredge Hersh & Jardine, P.C.;
Legal Alert/Article
September 10, 2014, previously published on August 27, 2014
The U.S. Drug Enforcement Administration has reclassified hydrocodone combination medications from Schedule III to Schedule II, increasing the restrictions on the drugs. Hydrocodone alone is already a Schedule II drug, but now medications that use a mixture of hydrocodone and another medication,...

 

HTMLBrand-Name Drug Manufacturer Liable For Personal Injuries Caused By Generic Drugs Manufactured By Different Company In Alabama
Sutherland Asbill Brennan LLP;
Legal Alert/Article
September 4, 2014, previously published on August 25, 2014
The Supreme Court of Alabama held last week that under Alabama law, a brand-name drug company can be held liable for fraud or misrepresentation based on statements made in connection with the manufacture of a brand-name prescription drug by a plaintiff claiming physical injury cause by a generic...

 

HTMLFDA Releases Guidance for Industry on ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers
Duane Morris LLP;
Legal Alert/Article
July 8, 2014, previously published on June 20, 2014
The U.S. Food and Drug Administration (FDA) recently published a new Guidance for Industry, titled ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers, which provides answers to questions from public comments received on the draft Guidance for Industry on ANDAs:...

 

HTMLFDA Issues Draft Guidance for Identification and Notification of Suspect Products
Duane Morris LLP;
Legal Alert/Article
July 8, 2014, previously published on June 24, 2014
As discussed in our April 11, 2014 Alert, the Drug Supply Chain Security Act (DSCSA) was enacted "to build an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed within the United States." Recently, the U.S. Food and Drug...

 

HTMLHow the Supreme Court Decision in Alice Corp. v. CLS Bank Undermines the USPTO Subject Matter Eligibility Guidance
Courtenay C. Brinckerhoff; Foley & Lardner LLP;
Legal Alert/Article
June 30, 2014, previously published on June 24, 2014
On June 19, 2014, the Supreme Court issued its decision in Alice Corp. v. CLS Bank International, finding that patents directed to “a computer-implemented scheme for mitigating ‘settlement risk’” were invalid as being drawn to a patent-ineligible abstract idea. Although the...

 

HTMLUPDATE: The Hare Loses Steam - Patent Litigation Reform Law Unlikely This Year
Ann G. Fort; Sutherland Asbill & Brennan LLP;
Legal Alert/Article
May 27, 2014, previously published on May 23, 2014
Efforts by the U.S. Senate to pass an alternative to the Innovation Act, which aims to reform abusive patent litigation, have stalled. Sen. Patrick Leahy, who is leading the effort, has announced that his committee is tabling that work until the interested parties reach a bipartisan compromise....

 

HTMLFederal Jury Awards Punitive Damages In Actos Bladder Cancer Trial
Stephen H. Cassidy; Lieff, Cabraser, Heimann & Bernstein, LLP;
Legal Alert/Article
April 22, 2014, previously published on April 8, 2014
A federal jury in Louisiana yesterday ordered Takeda Pharmaceutical Company and Eli Lilly & Company to pay $1,475,000 in compensatory damages, finding that they failed to adequately warn about bladder-cancer risks of their diabetes medicine Actos. Jurors also found that Takeda and Lilly...

 

HTMLActos Decision Statement: $9 Billion Decision on Eli Lilly and Takeda Pharmaceuticals
Motley Rice;
Legal Alert/Article
April 11, 2014, previously published on April 8, 2014
On Monday, April 7, a federal court jury in Louisiana decided that Takeda Pharmaceuticals and Eli Lilly hid the risks of bladder cancer from the diabetes drug, Actos. Takeda was ordered to pay $6 billion and Eli Lilly was ordered to pay $3 billion.

 


View Page: 1  2  3  4  5  6  7  8  9  10  Next  >>